Turning biodefense dollars into products.
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
Trull
Melanie C
MC
BioAbility, LLC, PO Box 14569, Research Triangle Park, North Carolina 27709, USA. mtrull@bioability.com
du Laney
Tracey V
TV
Dibner
Mark D
MD
D001709:Biotechnology / Q000191:economics*; D023482:Bioterrorism / Q000191:economics* / Q000517:prevention & control; D002959:Civil Defense / Q000191:economics*; D015510:Clinical Medicine / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D018581:Technology Transfer; D014481:United States; D014612:Vaccines / Q000191:economics*
D014612:Vaccines